ERBB2 and breast cancer: Additionally, in the same study, the analysis of 40 BC specimens revealed that the HER2+ CD44high/CD24low BCSC population was more frequently detected in recurrent BC than in primary BC [56], suggesting that the CD44high/CD24low compartment is particularly refractory to anticancer therapy.